PXD002765

PXD002765 is an original dataset announced via ProteomeXchange.

Title	Proteomics analysis of synergistic drug combination of midostaurin and BMS-754807 in Ewing sarcoma ASP14 cell line
Description	We used quantitative mass spectrometry-based proteomics to unravel global changes in the phosphoproteome upon treatment of ASP14 cells (a Ewing Sarcoma cell line) according to the setup below. The combination of drugs were experimentally shown to infer synergy in terms of cell killing. Three experiments were performed using a triple SILAC setup (Light: Lys0,Arg0; Medium: Lys4,Arg6; and Heavy: Lys8,Arg10): Experiment 1: Light SILAC: Drug combination (90 nM Midostaurin + 20 nM BMS-754807) Medium SILAC: Midostaurin (90 nM) Heavy SILAC: 0.1% DMSO Experiment 2: Light SILAC: Drug combination (90 nM Midostaurin + 20 nM BMS-754807) Medium SILAC: Midostaurin (90 nM) Heavy SILAC: BMS-754807 (20 nM) Experiment 3: Light SILAC: Drug combination (90 nM Midostaurin + 20 nM BMS-754807) Medium SILAC: BMS-754807 (20 nM) Heavy SILAC: 0.1% DMSO ASP14 cells were starved by replacing complete SILAC medium with SILAC minimal medium without serum over night. Cells were treated with drugs as stated above for 2h; then they were stimulated with serum for 20 minutes and harvested thereafter.
HostingRepository	PRIDE
AnnounceDate	2024-10-22
AnnouncementXML	Submission_2024-10-22_04:25:04.598.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Kristina Bennet Emdal
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	phosphorylated residue
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2015-08-19 05:28:57	ID requested
1	2017-04-19 02:47:29	announced
⏵ 2	2024-10-22 04:25:11	announced	2024-10-22: Updated project metadata.

Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G, Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. Mol Cancer Ther, 16(1):88-101(2017) [pubmed]

10.1158/1535-7163.MCT-16-0235;

curator keyword: Biomedical

submitter keyword: Human, LC-MSMS, drug synergy, Ewing Sarcoma

Jesper Velgaard Olsen
contact affiliation	Jesper V. Olsen, Novo Nordisk Foundation Center for Protein Research, Faculty of Health & Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.
contact email	jesper.olsen@cpr.ku.dk
lab head
Kristina Bennet Emdal
contact affiliation	NNF Center for Protein Research, Proteomics Program, Faculty of Health and Medical Sciences, University of Copenhagen.
contact email	kristina.emdal@cpr.ku.dk
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2017/04/PXD002765

PRIDE project URI

• PRIDE
  1. PXD002765
     1. Label: PRIDE project
     2. Name: Proteomics analysis of synergistic drug combination of midostaurin and BMS-754807 in Ewing sarcoma ASP14 cell line